Reagents for PD-1 research
ichorbio supplies a large range of products related to PD-1 including low endotoxin antibodies, biosimilar antibodies, conjugated antibodies and recombinant proteins.
Low Endotoxin in vivo Antibodies to PD-1
ichorbio sells three clones to PD-1 – 29F.1A12, J43 and RMP1-14. We have provided these in low endotoxin, azide and BSA free formats for in vivo research.
Biosimilar Antibodies that target PD-1
ichorbio supplies two antibodies which target PD-1: Nivolumab and Pembrolizumab. Both antibodies are strictly for research use only; they are not medicinal grade and therefore are not for therapeutic purposes.
Conjugated antibodies to PD-1
ichorbio supplies a range of conjugated antibodies to PD-1, including antibodies conjugated to the DyLight dyes
Inhibitors to PD-1
ichorbio supplies three inhibitors which target PD-1/PD-L1 interactions.
Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PD-L1
and CD273/PD-L2. Following T-cell receptor (TCR) engagement, PD-1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PD-1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity).
The PD-1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with CD274/PD-L1
inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PD-1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
Inhibited by pembrolizumab
(also named MK-3475 or lambrolizumab), a monoclonal antibody that prevents the interaction with CD274/PD-L1.
Inhibited by nivolumab
(also named ONO-4538, BMS-936558 or Opdivo), a monoclonal antibody that prevents the interaction with CD274/PD-L1. The interaction with nivolumab is not dependent on glycosylation and depends on a loop at the N-terminus (N-terminal loop, corresponding to residues 25-34). Targeting the interaction between PD-1 and CD274/PD-L1 with pembrolizumab and nivolumab antibodies has demonstrated great promise as a strategy for controlling and eradicating cancer. Pembrolizumab and nivolumab are used for treatment of patients with advanced melanoma. These antibodies are also effective against other cancers, such as non-small cell lung cancer, renal cell carcinoma, bladder cancer and Hodgkin’s lymphoma.